Mitral heart disease due to cabergoline.
The case of a restrictive valve disease associated with cabergoline, an ergot alkaloid agonist used in the treatment of Parkinson's disease, is described. Cardiovascular and periodical follow-up assessment may be required when these drugs are prescribed.
Martin
Maria
M
Iglesias-Cubero
Gustavo
G
Diaz Molina
Beatriz
B
Moris De la Tassa
Cesar
C
D000978:Antiparkinson Agents / Q000009:adverse effects*; D000077465:Cabergoline; D004873:Ergolines / Q000009:adverse effects*; D005260:Female; D006349:Heart Valve Diseases / Q000139:chemically induced*; D006801:Humans; D008875:Middle Aged; D008944:Mitral Valve Insufficiency / Q000139:chemically induced*
D000978:Antiparkinson Agents; D004873:Ergolines; D000077465:Cabergoline